Fertility and sterility · 2006
Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Checa Miguel A, Prat María, Robles Ana, Carreras Ramón
Аннотация
OBJECTIVE: To assess the usefulness of the GnRH antagonist cetrorelix to prevent LH surge and to avoid intrauterine insemination at weekends when a gynecologist on duty is not available and the ultrasound scan on Friday showed > 1 and < 3 follicles > or = 17 mm in diameter.
DESIGN: Open-label, randomized, prospective study.
SETTING: Reproductive medicine unit in an acute care teaching hospital in Barcelona, Spain.
PATIENT(S): Infertile patients undergoing controlled ovarian hyperstimulation (COH) and IUI.
INTERVENTION(S): Treatment with recombinant FSH was started on day 3. In women assigned to the control group (n = 32), recombinant FSH was continued up to the day of hCG administration. In patients assigned to the GnRH antagonist group (n = 35), half of the dose of recombinant FSH was given for 2 more days in addition to cetrorelix (0.25 mg SC) until the day of hCG administration.
MAIN OUTCOME MEASURE(S): Recombinant FSH doses, E(2) level on the day of hCG administration, number and diameter of follicles, endometrial thickness, and number of pregnancies.
RESULT(S): Only a case of premature ovulation occurred in the cetrorelix group. There were no significant differences between the study groups in the total mean number of follicles, follicles > 10 mm and < 17 mm, and follicles > or = 17 mm. The mean concentration of E2 on the day of hCG administration and the endometrial thickness were significantly higher in the cetrorelix group. Eleven pregnancies were achieved, 7 (20%) in the cetrorelix group (4 singleton, 3 twins) and 4 (12.5%) in controls (4 singleton). No case of ovarian hyperstimulation syndrome (OHSS) occurred.
CONCLUSION(S): The use of cetrorelix to avoid IUI at weekends when the ultrasound scan on Friday shows > 1 and < 3 follicles > or = 17 mm is a useful alternative for medical centers in which a gynecologist on call is not available.
DESIGN: Open-label, randomized, prospective study.
SETTING: Reproductive medicine unit in an acute care teaching hospital in Barcelona, Spain.
PATIENT(S): Infertile patients undergoing controlled ovarian hyperstimulation (COH) and IUI.
INTERVENTION(S): Treatment with recombinant FSH was started on day 3. In women assigned to the control group (n = 32), recombinant FSH was continued up to the day of hCG administration. In patients assigned to the GnRH antagonist group (n = 35), half of the dose of recombinant FSH was given for 2 more days in addition to cetrorelix (0.25 mg SC) until the day of hCG administration.
MAIN OUTCOME MEASURE(S): Recombinant FSH doses, E(2) level on the day of hCG administration, number and diameter of follicles, endometrial thickness, and number of pregnancies.
RESULT(S): Only a case of premature ovulation occurred in the cetrorelix group. There were no significant differences between the study groups in the total mean number of follicles, follicles > 10 mm and < 17 mm, and follicles > or = 17 mm. The mean concentration of E2 on the day of hCG administration and the endometrial thickness were significantly higher in the cetrorelix group. Eleven pregnancies were achieved, 7 (20%) in the cetrorelix group (4 singleton, 3 twins) and 4 (12.5%) in controls (4 singleton). No case of ovarian hyperstimulation syndrome (OHSS) occurred.
CONCLUSION(S): The use of cetrorelix to avoid IUI at weekends when the ultrasound scan on Friday shows > 1 and < 3 follicles > or = 17 mm is a useful alternative for medical centers in which a gynecologist on call is not available.
Предметные рубрики MeSH
AdultAppointments and SchedulesChorionic GonadotropinDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationEndometriumEstradiolFemaleFollicle Stimulating HormoneGonadotropin-Releasing HormoneHormone AntagonistsHumansInfertilityInsemination, ArtificialLuteinizing HormoneOvarian FolliclePregnancyPregnancy RateRecombinant ProteinsUltrasonography